Comorbidities and health‐related quality of life in Spanish patients with moderate to severe psoriasis: A cross‐sectional study (Arizona study)

Sánchez‐Carazo, J.L.; López-Estebaranz, J.L.; Guisado, Cristina

doi:10.1111/1346-8138.12465

Cited by 57 publications

(60 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pattern of factors associated with a poorer general health status observed in our study is consistent with past published observations . A higher impact of psoriasis on women's HRQoL compared to men has previously been reported .…”

Section: Discussionsupporting

confidence: 92%

Use of the SF‐12 questionnaire to assess physical and mental health status in patients with psoriasis

Sampogna

Mastroeni

Pallotta

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Health‐related quality of life (HRQoL) in psoriasis patients is generally measured using disease‐ or dermatology‐specific questionnaires. Our objective was to use the generic 12‐item Short Form Health Survey (SF‐12) instrument to measure the physical and mental impact of psoriasis and to compare scores with those already published for different diseases. An observational study was conducted among mild‐to‐severe psoriasis outpatients. Health status was assessed by the SF‐12, which includes a physical (PCS) and a mental (MCS) scale. The 12‐item General Health Questionnaire (GHQ‐12) was used to assess the possible presence of depression or anxiety, and the Skindex‐17 to measure dermatology‐specific HRQoL. Statistical analyses were performed to estimate the association between physical and mental health status and demographic and clinical characteristics. The study population included 1592 patients. Psoriasis PCS scores were similar to the general population and to non‐severe diseases such as allergies, dermatitis, or back pain, while MCS mean scores were very similar to that of depression, and lower than those of all the other chronic conditions. Poor physical health was associated with female sex, older age, lower educational level, joint involvement, ≥2 comorbidities, moderate to very severe clinical status, GHQ‐12 score ≥4, and moderate to severe Skindex‐17 psychosocial scores. Poor mental health was associated with younger age (<30 years), GHQ ≥ 4, and severe Skindex‐17 psychosocial scores. In conclusion, a general health measure, such as the SF‐12, appears to be able to capture, in psoriasis patients, the burden of the disease both from a physical and a mental point of view.

show abstract

Section: Discussionsupporting

confidence: 92%

Use of the SF‐12 questionnaire to assess physical and mental health status in patients with psoriasis

Sampogna

Mastroeni

Pallotta

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The ARIZONA study was a multicenter, cross‐sectional, observational epidemiological study conducted at 68 dermatology‐based centers across Spain. It was designed to determine the correlation between QoL and the associated comorbid diseases in patients with psoriasis . All patients gave written informed consent to the use of their data prior to inclusion and the study was approved by the Independent Research Ethics Committee at Hospital General Universitario de Valencia (Valencia, Spain).…”

Section: Methodsmentioning

confidence: 99%

Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study

López-Estebaranz

Sánchez‐Carazo

Sulleiro³

2015

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease whose clinical characteristics vary from patient to patient. We aimed to analyze how comorbidities and quality of life (QoL, as per the Dermatology Life Quality Index [DLQI]) may be affected by a family history of psoriasis and by age. The ARIZONA study was a multicenter, cross-sectional study in 1022 adult patients diagnosed with moderate to severe psoriasis at least 6 months prior to inclusion. The severity of psoriasis and the proportion of patients with comorbidities were not affected by the presence of a family history. The regression analysis revealed that the presence of a family history of psoriasis was associated with the effect on the patient's QoL (P = 0.002), regardless of disease severity. The mean DLQI total score varied significantly across age groups (5.1 ± 5.3 for the 18-30-year group, 5.7 ± 6.5 for the 31-60-year group and 3.8 ± 5.1 for the >60-year group; P = 0.001). In conclusion, the presence of a family history of psoriasis appears to disrupt QoL in patients with moderate to severe psoriasis, but it hardly affected the prevalence of comorbid conditions. The effect of age on QoL was particularly noticeable in younger patients, highlighting its negative impact. As expected, older patients appeared to be burdened with a higher number of comorbidities than their younger counterparts.

show abstract

“…itching and pain) had the greatest effect on HRQoL. ARIZONA, a large, cross‐sectional, observational study conducted in Spain, evaluated comorbidities in 1022 patients with moderate‐to‐severe psoriasis . The most common comorbidities associated with psoriasis were dyslipidemia (28.1% of patients), obesity (26.0%), psoriatic arthritis (21.8%) and hypertension (18.3%).…”

Section: Discussionmentioning

confidence: 99%

A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain

Puig

Kerkhof

Reich

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundThe Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC).ObjectiveTo utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI).MethodsThe MAPP survey was conducted between June and August 2012. This analysis included 1700 patients with self‐reported psoriasis (without psoriatic arthritis) from France (n = 349), Germany (n = 311), Italy (n = 359), Spain (n = 354) and the United Kingdom (n = 327).ResultsPatients from Spain vs. other EC self‐reported higher mean body mass index (26.9 vs. 25.6, P ≤ 0.001), lower prevalence of depression (6% vs. 12%, P = 0.002) and higher mean self‐perceived psoriasis severity at its worst (5.92 vs. 5.33, P < 0.001) despite lower estimated body‐surface‐area involvement. Overall, patients from Spain vs. other EC had lower mean global DLQI scores (4.70 vs. 6.06, P = 0.001) and lower mean scores for each DLQI dimension [all P < 0.001, except leisure (P = 0.002), treatment (P = 0.002), and work and school (P = 0.005)]. Higher DLQI values were inversely associated with age and directly correlated with perceived severity. Palmoplantar, nail and scalp psoriasis were reported less frequently in Spanish patients (P = 0.026) and were associated with higher DLQI values (P < 0.01). Spanish patients were more likely to have seen multiple healthcare providers (HCPs; P < 0.001) and achieve therapeutic goals (P < 0.001), but current treatments were similar to patients in other EC.ConclusionsIn the MAPP survey, Spanish patients differed from other EC in several characteristics, including comorbidities, extent and distribution of psoriasis lesions, perception of severity and impact on quality of life. Their perception of psoriasis severity was higher despite a lower estimated extent, and DLQI scores were significantly lower. Spanish patients had more HCP visits and a higher rate of therapeutic goal achievement. These differences might be attributed to cultural factors, phenotypical variation and differences in HCP access.

show abstract

Comorbidities and health‐related quality of life in Spanish patients with moderate to severe psoriasis: A cross‐sectional study (Arizona study)

Cited by 57 publications

References 35 publications

Use of the SF‐12 questionnaire to assess physical and mental health status in patients with psoriasis

Use of the SF‐12 questionnaire to assess physical and mental health status in patients with psoriasis

Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study

A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain

Contact Info

Product

Resources

About